Pharmaceutical Preparations · SIC 2834

ARROWHEAD PHARMACEUTICALS, INC.

ARWR

Watch

Latest revenue

$73.7M

as of 2026-03-31

Latest net income

$-101.9M

as of 2026-03-31

Net margin

-138.2%

as of 2026-03-31

Price · 5Y

+0.6% / yr 13.1 pts / yr vs S&P 500 3.2% total
Compare:

Live market

delayed ≤15 min
$74.95
0.78%
Market cap
$10.56B
Enterprise value
$10.56B
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$82.26
52-wk low
$14.30
Beta
Shares out
140.9M

5-year trend

About ARWR

Business description and risk factors will appear here once ARWR's latest filing is fully ingested.

Profitability

Operating margin

11.9%

100.1%

Net margin

-0.2%

100.0%

Return on equity

-0.3%

99.9%

Return on assets

-0.1%

99.8%

Leverage

Debt / equity

1.97×

61.7%

Long-term debt / equity

0.46×

78.3%

Debt / assets

66.4%

20.7%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$73.7M-86.4%$-101.9M-151.6%-138.2%

Q4 2025

2025-12-31

$264.0M+10461.3%$30.8M+117.8%11.7%

Q3 2025

2025-09-30

$256.5M$-48.0M+71.8%-18.7%

Q2 2025

2025-06-30

$27.8M$22.1M+113.0%79.7%

Q1 2025

2025-03-31

$542.7M$197.4M+257.5%36.4%

Q4 2024

2024-12-31

$2.5M-29.6%$-173.1M-30.3%-6923.4%

Q3 2024

2024-09-30

$0$-170.5M

Q2 2024

2024-06-30

$0-100.0%$-170.8M-78.7%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Pharmaceutical Preparations · SIC 2834

No data yet for industry average

Your notes

Keep private notes on ARWR — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$0

Insider selling

$37.9M

Net activity

−$37.9M

Distinct insiders

10

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-05-12

Hongbo Lu

Director

Sale2,970$76.88$228.3K
2026-04-23

James C Hamilton

Chief Medical Officer

Sale10,000$75.00$750.0K
2026-04-22

Daniel Joseph Apel

Chief Financial Officer

Sale3,208$70.11$224.9K
2026-04-22

Daniel Joseph Apel

Chief Financial Officer

Sale1,157$70.45$81.5K
2026-04-22

Daniel Joseph Apel

Chief Financial Officer

Sale8,730$71.92$627.9K
2026-03-05

James C Hamilton

Chief Medical Officer

Sale10,000$64.19$641.9K
2026-01-05

Patrick O'Brien

COO

Sale4,368$61.20$267.3K
2026-01-05

Patrick O'Brien

COO

Sale6,164$62.23$383.6K
2026-01-05

Patrick O'Brien

COO

Sale13,451$62.96$846.9K
2026-01-05

Patrick O'Brien

COO

Sale11,842$63.84$756.0K
2026-01-05

Patrick O'Brien

COO

Sale2,700$64.44$174.0K
2026-01-05

Patrick O'Brien

COO

Sale900$66.01$59.4K
2026-01-05

Patrick O'Brien

COO

Sale313$68.00$21.3K
2026-01-05

Patrick O'Brien

COO

Sale600$61.12$36.7K
2026-01-05

Patrick O'Brien

COO

Sale900$62.25$56.0K
2026-01-05

Patrick O'Brien

COO

Sale5,873$62.91$369.5K
2026-01-05

Patrick O'Brien

COO

Sale2,336$64.04$149.6K
2026-01-05

Patrick O'Brien

COO

Sale46$68.00$3.1K
2026-01-05

James C Hamilton

Chief Medical Officer

Sale4,625$61.24$283.2K
2026-01-05

James C Hamilton

Chief Medical Officer

Sale6,090$62.28$379.3K
2026-01-05

James C Hamilton

Chief Medical Officer

Sale14,792$63.01$932.0K
2026-01-05

James C Hamilton

Chief Medical Officer

Sale12,711$63.95$812.9K
2026-01-05

James C Hamilton

Chief Medical Officer

Sale1,200$64.49$77.4K
2026-01-05

James C Hamilton

Chief Medical Officer

Sale437$65.97$28.8K
2026-01-05

James C Hamilton

Chief Medical Officer

Sale309$68.00$21.0K
2026-01-02

Christopher Richard Anzalone

Chief Executive Officer

Sale7,416$65.88$488.6K
2026-01-02

Christopher Richard Anzalone

Chief Executive Officer

Sale5,771$66.39$383.1K
2025-12-29

Christopher Richard Anzalone

Chief Executive Officer

Sale35,181$69.33$2.4M
2025-12-29

Christopher Richard Anzalone

Chief Executive Officer

Sale16,545$68.69$1.1M
2025-12-26

Mauro Ferrari

Director

Sale7,530$70.00$527.1K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns ARWR

Institutional value

$3.47B

Total shares held

56.0M

Distinct holders

266

-132 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1BlackRock, Inc.18.2M$1.14B-3.2M (-14.8%)Trimmed
2VANGUARD PORTFOLIO MANAGEMENT LLC7.1M$448.1MNew
3VANGUARD CAPITAL MANAGEMENT LLC6.0M$378.2MNew
4Invesco Ltd.3.3M$205.7M+2.7M (+498.9%)Added
5UBS Group AG1.3M$83.8M+349.0K (+35.3%)Added
6UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1.3M$83.5M+70.6K (+5.6%)Added
7Pictet Asset Management Holding SA1.3M$79.6M+244.5K (+23.8%)Added
8Fisher Asset Management, LLC1.1M$69.8M-198.2K (-15.1%)Trimmed
9VANGUARD FIDUCIARY TRUST CO965.8K$60.6MNew
10Bank of New York Mellon Corp960.1K$60.2M+72.3K (+8.1%)Added
11Connor, Clark & Lunn Investment Management Ltd.837.0K$52.5M+173.7K (+26.2%)Added
12Western Financial Corp/CA820.2K$51.4M+0 (+0.0%)No change
13Voya Investment Management LLC656.1K$41.1M+233.4K (+55.2%)Added
14BNP PARIBAS FINANCIAL MARKETS650.6K$40.8M+610.2K (+1510.5%)Added
15JPMORGAN CHASE & CO683.1K$39.4M+71.2K (+11.6%)Added
16DIMENSIONAL FUND ADVISORS LP608.5K$38.1M+461.1K (+312.8%)Added
17Nuveen, LLC499.8K$31.3M+211.3K (+73.2%)Added
18PRINCIPAL FINANCIAL GROUP INC490.1K$30.7M-225.4K (-31.5%)Trimmed
19FRANKLIN RESOURCES INC462.7K$29.0M+355.3K (+331.0%)Added
20RHUMBLINE ADVISERS404.4K$25.4M+52.0K (+14.8%)Added

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once ARWR's latest filing finishes processing.